Sparx Therapeutics-News release 2018-11-8
November 9, 2018
Sparx Therapeutics & KPC Pharmaceutical Sign Agreement for the Development of anti-Claudin 18.2 Antibodies Sparx Therapeutics, Inc. has signed an agreement with KPC Pharmaceutical to
